Evommune (EVMN) Cash & Equivalents (2024 - 2026)

Evommune (EVMN) has 3 years of Cash & Equivalents data on file, last reported at $48.3 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 747.09% year-over-year to $48.3 million in Q1 2026; TTM through Mar 2026 was $48.3 million, a 747.09% increase from a year earlier, with the FY2025 full-year figure at $44.1 million, up 171.07% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $48.3 million, up from $44.1 million in the prior quarter.
• Over the last five years, Cash & Equivalents for EVMN reached as high as $48.3 million in Q1 2026 and fell as low as $5.7 million in Q1 2025.
• Historically, Cash & Equivalents has averaged $26.6 million across 3 years, with a median of $22.5 million in 2024.
• Across the five-year window, Cash & Equivalents surged 47.79% in 2025 and jumped 747.09% in 2026, its largest moves.
• Year by year, Cash & Equivalents stood at $16.3 million in 2024, then surged by 171.07% to $44.1 million in 2025, then increased by 9.66% to $48.3 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $48.3 million in Q1 2026, $44.1 million in Q4 2025, and $26.8 million in Q3 2025.